The new pneumococcal vaccine

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years. The prevalence of pneumococcal disease worldwide and the alarming global escalation of multiresistant strains of Streptococcus pneumoniae (pneumococcus) during the past decade have provided the impetus for the development and application of a new pneumococcal vaccine. The outstanding success of Haemophilus influenzae type b (Hib) conjugate vaccine in the control of invasive Hib disease is a reason to be optimistic that the pneumococcal conjugate vaccines will achieve similar results for the control of invasive pneumococcal disease. Remarkable efficacy against invasive pneumococcal disease with a seven-valent pneumococcal conjugate vaccine was demonstrated in infants and toddlers in the USA, and in February 2000 the first pneumococcal conjugate vaccine was licensed. Licensure and widespread use is likely to follow in other countries in which there is a need and the means to afford this live-saving vaccine. Active disease surveillance must be sustained globally, while active research, development of other multivalent conjugate formulations and the search for new candidate protein-based vaccines are in progress.

Original languageEnglish (US)
Pages (from-to)623-633
Number of pages11
JournalClinical Microbiology and Infection
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

Pneumococcal Vaccines
Conjugate Vaccines
Haemophilus influenzae type b
Streptococcus pneumoniae
Vaccines
Bacterial Vaccines
Licensure
Research

Keywords

  • Pneumococcal diseases
  • Protein conjugate vaccine
  • Streptococcus pneumoniae

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

The new pneumococcal vaccine. / Obaro, S. K.

In: Clinical Microbiology and Infection, Vol. 8, No. 10, 01.10.2002, p. 623-633.

Research output: Contribution to journalArticle

@article{2147bf665e4b40c2a0d55a8f7a777e77,
title = "The new pneumococcal vaccine",
abstract = "Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years. The prevalence of pneumococcal disease worldwide and the alarming global escalation of multiresistant strains of Streptococcus pneumoniae (pneumococcus) during the past decade have provided the impetus for the development and application of a new pneumococcal vaccine. The outstanding success of Haemophilus influenzae type b (Hib) conjugate vaccine in the control of invasive Hib disease is a reason to be optimistic that the pneumococcal conjugate vaccines will achieve similar results for the control of invasive pneumococcal disease. Remarkable efficacy against invasive pneumococcal disease with a seven-valent pneumococcal conjugate vaccine was demonstrated in infants and toddlers in the USA, and in February 2000 the first pneumococcal conjugate vaccine was licensed. Licensure and widespread use is likely to follow in other countries in which there is a need and the means to afford this live-saving vaccine. Active disease surveillance must be sustained globally, while active research, development of other multivalent conjugate formulations and the search for new candidate protein-based vaccines are in progress.",
keywords = "Pneumococcal diseases, Protein conjugate vaccine, Streptococcus pneumoniae",
author = "Obaro, {S. K.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1046/j.1469-0691.2002.00424.x",
language = "English (US)",
volume = "8",
pages = "623--633",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - The new pneumococcal vaccine

AU - Obaro, S. K.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years. The prevalence of pneumococcal disease worldwide and the alarming global escalation of multiresistant strains of Streptococcus pneumoniae (pneumococcus) during the past decade have provided the impetus for the development and application of a new pneumococcal vaccine. The outstanding success of Haemophilus influenzae type b (Hib) conjugate vaccine in the control of invasive Hib disease is a reason to be optimistic that the pneumococcal conjugate vaccines will achieve similar results for the control of invasive pneumococcal disease. Remarkable efficacy against invasive pneumococcal disease with a seven-valent pneumococcal conjugate vaccine was demonstrated in infants and toddlers in the USA, and in February 2000 the first pneumococcal conjugate vaccine was licensed. Licensure and widespread use is likely to follow in other countries in which there is a need and the means to afford this live-saving vaccine. Active disease surveillance must be sustained globally, while active research, development of other multivalent conjugate formulations and the search for new candidate protein-based vaccines are in progress.

AB - Pneumococcal disease is now the leading cause of vaccine-preventable bacterial disease in children worldwide. Although a pneumococcal polysaccharide vaccine has been available for over three decades, its use has been limited due to poor immunogenicity in the most vulnerable children, aged less than 2 years. The prevalence of pneumococcal disease worldwide and the alarming global escalation of multiresistant strains of Streptococcus pneumoniae (pneumococcus) during the past decade have provided the impetus for the development and application of a new pneumococcal vaccine. The outstanding success of Haemophilus influenzae type b (Hib) conjugate vaccine in the control of invasive Hib disease is a reason to be optimistic that the pneumococcal conjugate vaccines will achieve similar results for the control of invasive pneumococcal disease. Remarkable efficacy against invasive pneumococcal disease with a seven-valent pneumococcal conjugate vaccine was demonstrated in infants and toddlers in the USA, and in February 2000 the first pneumococcal conjugate vaccine was licensed. Licensure and widespread use is likely to follow in other countries in which there is a need and the means to afford this live-saving vaccine. Active disease surveillance must be sustained globally, while active research, development of other multivalent conjugate formulations and the search for new candidate protein-based vaccines are in progress.

KW - Pneumococcal diseases

KW - Protein conjugate vaccine

KW - Streptococcus pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0036805254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036805254&partnerID=8YFLogxK

U2 - 10.1046/j.1469-0691.2002.00424.x

DO - 10.1046/j.1469-0691.2002.00424.x

M3 - Article

C2 - 12390280

AN - SCOPUS:0036805254

VL - 8

SP - 623

EP - 633

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 10

ER -